TScan Therapeutics Announces Pricing of Upsized $150 Million Public Offering

2 years ago

WALTHAM, Mass., April 17, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the…

Health Advocate Applauds Federal Budget 2024 in providing costing on a National Pharmacare Plan; a milestone in universal free access to contraceptives

2 years ago

OTTAWA, April 16, 2024 (GLOBE NEWSWIRE) -- The Society of Obstetricians and Gynaecologists of Canada (SOGC) applauds the federal government’s…

Nurix Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

2 years ago

SAN FRANCISCO, April 16, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX) today announced the closing of its underwritten public…

Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)

2 years ago

SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between…

Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)

2 years ago

SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between…

Panbela Announces Transfer to OTCQB Market

2 years ago

MINNEAPOLIS, April 16, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for…

Cingulate to Participate in Planet MicroCap Showcase: Vegas 2024

2 years ago

KANSAS CITY, Kan., April 16, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision…

INVO Reports Fourth Quarter and Full Year 2023 Financial Results

2 years ago

SARASOTA, Fla., April 16, 2024 (GLOBE NEWSWIRE) -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a healthcare services…

CVRx to Report First Quarter 2024 Financial and Operating Results and Host Conference Call on April 30th, 2024

2 years ago

MINNEAPOLIS, April 16, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing,…

HOOKIPA Pharma Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

2 years ago

NEW YORK and VIENNA, Austria, April 16, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing…